FDA Approves OTC Naloxone Nasal Spray Rextovy to Expand Opioid Overdose Reversal Access 
On June 16, 2026, the U.S. Food and Drug Administration (FDA) approved Rextovy (naloxone hydrochloride…
John EvansJune 18, 2026
Latest News
Katie Montenegro Promoted to Associate VP Project Management
PEGUS Research is very excited to announce the addition of Katie Montenegro to our Executive…
John EvansJanuary 3, 2025
FDA Approves First-In-Class OTC Contraceptive!
On July 13, 2023, the FDA approved the first nonprescription progestin-only oral contraceptive pill in…
John EvansJuly 13, 2023
FDA Approves First-In-Class OTC Naloxone Nasal Spray!
On March 29, 2023, the FDA approved the first OTC naloxone nasal spray in the…
John EvansMarch 29, 2023
New Staff
PEGUS is pleased to announce the following additions to our team: Lisa Fairfax, MBA: Lisa is…
John EvansFebruary 8, 2023
Upcoming FDA Advisory Committee Meetings
Key staff from PEGUS are pleased to participate in two upcoming public FDA advisory committee…
John EvansFebruary 8, 2023
Application for First OTC Birth Control Pill in the US
On July 11, a prominent PEGUS Research sponsor submitted its application to the FDA for…
John EvansJuly 14, 2022
PEGUS Research Embraces and Expands WFH Model
On May 26, PEGUS Research CEO Clark Richardson announced features of the company’s enhanced work-from-home…
John EvansJune 14, 2022
